Infantile hemangiomas — commonly called 'strawberry marks' — are the most frequent benign vascular tumors in infants, affecting 4–5% of all babies. Most appear within the first 2–4 weeks of life, grow rapidly until ~5 months, then gradually involute over years. While 90% resolve without intervention by age 10, high-risk lesions (e.g., those near eyes, airway, or ulcerating) require prompt evaluation. This article provides actionable, evidence-based guidance from pediatric nursing and dermatology practice, including FDA-approved treatment thresholds, growth timelines, and real-world monitoring tools used at institutions like Boston Children’s Hospital and Cincinnati Children’s.
What Is an Infantile Hemangioma?
An infantile hemangioma (IH) is a proliferative, benign tumor composed of immature endothelial cells. Unlike vascular malformations (e.g., port-wine stains), IHs are characterized by rapid postnatal growth followed by spontaneous involution. They are not present at birth in >90% of cases; instead, they manifest as faint red or bluish macules or small papules that darken and enlarge over weeks. Histologically, IHs show GLUT-1 protein positivity — a key diagnostic marker distinguishing them from other vascular anomalies.
The American Academy of Pediatrics (AAP) defines IHs as self-limited vascular proliferations with three distinct phases: proliferation (birth to ~5 months), plateau (5–8 months), and involution (starting ~9 months, lasting up to 10 years). During proliferation, hemangiomas can increase in volume by 30–50% per month. A landmark 2019 Cochrane review confirmed that untreated IHs involute completely in 69% of children by age 5 and in 90% by age 10.
How Common Are They?
Epidemiologic data from the CDC and multiple cohort studies show IH incidence varies by race and sex. White infants have the highest rate: 4.5–5.0%. Hispanic infants follow at 2.6%, Black infants at 1.4%, and Asian infants at 1.9%. Female infants are affected 3–5 times more often than males. Prematurity significantly increases risk: among infants born <28 weeks gestation, prevalence reaches 22–26%, per data published in Pediatrics (2021;147:e2020027625).
Family history matters: 10–15% of infants with IH have a first-degree relative with a prior hemangioma. Maternal factors — including placental abnormalities, preeclampsia, and chorionic villus sampling — are associated with modestly elevated risk, though causality remains unproven.
Recognizing the Three Clinical Stages
Accurate staging guides clinical decisions and reassures families. Nurses use standardized observation windows — especially during well-child visits at 2, 4, and 6 months — to assess progression.
Proliferative Phase (Birth–5 Months)
This phase begins days to weeks after birth and peaks around 3–5 months. Lesions become raised, bright red, and rubbery. Growth is most aggressive between weeks 4 and 12. A study of 1,247 IHs tracked via serial photography at Texas Children’s Hospital found median volume increase was 42% per month during peak proliferation. Ulceration occurs in 10–15% of proliferating IHs — most commonly on lip, diaper area, or neck — and carries infection risk and significant pain.
Parents should be taught to monitor for subtle signs: increased warmth, new surface crusting, bleeding, or inconsolable crying during diaper changes or feeding. At Children’s Hospital Los Angeles, nurses use the Hemangioma Activity Score (HAS), a validated 5-point tool assessing color intensity, surface texture, and palpable warmth.
Plateau Phase (5–8 Months)
Growth slows markedly. Lesions stabilize in size and may begin softening at edges. Color may deepen to burgundy or develop grayish areas as early involution begins. This phase lasts ~3 months but varies — some IHs plateau as early as 4 months; others extend to 9 months.
During this time, caregivers should document lesion dimensions monthly using a standardized ruler (e.g., AccuRuler® Pediatric Edition, calibrated to 0.1 cm). Consistent measurement technique — always taken at the same time of day, with infant supine and relaxed — improves longitudinal accuracy.
Involution Phase (Starting ~9 Months)
Involution is gradual and asymmetric. The earliest sign is color fading from bright red to dull red or purple-gray. Texture softens, and surface becomes wrinkled or flaccid. Median time to 50% involution is 3.5 years; to 75%, 5.2 years; and to 90%, 7.8 years (per 2022 meta-analysis in JAMA Dermatology). Residual changes — such as telangiectasias, fibrofatty tissue, or mild skin laxity — persist in 30–50% of cases, particularly with larger or deeper lesions.
When to Seek Immediate Evaluation
Not all hemangiomas require referral — but certain features demand urgent assessment by a pediatric dermatologist or vascular anomalies specialist. These are known as 'BARR' criteria: Bleeding/ulceration, Airway involvement, Risk to vision, and Risk of functional impairment.
- Airway involvement: Stridor, hoarse cry, or feeding difficulties suggest subglottic or laryngeal IH. Up to 60% of infants with beard-area (chin-to-ear) facial IH have concurrent airway hemangiomas, per data from the Vascular Anomalies Center at Cincinnati Children’s.
- Vision threat: Periorbital IHs >5 mm in diameter or those causing ptosis, strabismus, or astigmatism must be evaluated within 48 hours. Even small lesions over the upper eyelid can obstruct visual input and cause amblyopia.
- Ulceration: Present in 10–15% of IHs; highest risk in lip, nasal tip, and anogenital regions. Pain scores (using the FLACC scale) often exceed 6/10. Topical timolol 0.5% gel (FDA-approved for ulcerated IH) reduces pain and healing time by 40% versus placebo, per the 2020 TIMO-ULCER trial.
- Segmental distribution: Large, plaque-like IHs covering ≥5% of body surface area (BSA) — especially on face, trunk, or limbs — carry higher risk of PHACE syndrome (Posterior fossa malformations, Hemangioma, Arterial anomalies, Cardiac defects, Eye abnormalities). Screening MRI and echocardiogram are indicated before 1 month of age.
Other red flags include rapid growth beyond expected trajectory, sudden color change (e.g., blackening or necrosis), or associated neurologic symptoms (seizures, developmental delay), which may indicate underlying structural anomaly.
FDA-Approved Treatments and Evidence-Based Protocols
Since 2014, oral propranolol has been FDA-approved for IH requiring systemic therapy. It is dosed at 2–3 mg/kg/day divided BID, initiated in hospital under cardiac monitoring for infants <5 months or with risk factors (e.g., bronchopulmonary dysplasia, hypoglycemia history). Key brand formulations include Hemangeol® (oral solution, 4.28 mg/mL), the only FDA-labeled product, and generic propranolol oral solution (manufactured by Teva and Sandoz, bioequivalent per FDA Orange Book).
Treatment duration averages 6 months, though many clinicians extend to 12 months for high-risk lesions. A 2023 multicenter study (n=412) showed 89% of infants achieved ≥75% improvement by 6 months; discontinuation before 6 months correlated with 32% rebound growth vs. 7% with full-course treatment.
Topical Options for Superficial, Small Lesions
For IHs <2 cm in diameter and <1 mm thick, topical timolol maleate 0.5% gel (brand: Glaumax®) is first-line. Applied twice daily with clean fingertip, it achieves 50–60% reduction in volume by 16 weeks. Parents must avoid application near eyes or mucous membranes — accidental ocular exposure causes transient bradycardia in ~3% of cases, per AAD guidelines.
Timolol is contraindicated in infants with asthma, heart block, or severe heart failure. Nurses teach precise dosing: one 'pea-sized' amount covers ~10 cm². Over-application increases systemic absorption risk — blood levels rise significantly when >2 g applied daily, per pharmacokinetic modeling in Pediatric Dermatology (2021).
Procedural Interventions: When and Why
Laser therapy (pulsed dye laser, 595 nm) is reserved for residual telangiectasias or ulcerated lesions unresponsive to medical therapy. It does not reduce IH bulk during proliferation. At Boston Children’s Hospital, PDL is used at fluences of 6–8 J/cm² with dynamic cooling, typically requiring 3–5 sessions spaced 4–6 weeks apart.
Surgical excision is rarely needed — indicated only for fully involuted, disfiguring fibrofatty residua or persistent ulceration unresponsive to medical management. Postoperative scarring rates remain <5% with modern techniques (e.g., elliptical excision + layered closure), per 2022 outcomes data from the American Society of Plastic Surgeons.
Monitoring Tools and Home Care Strategies
Consistent tracking empowers families and informs clinical decisions. We recommend three validated methods:
- Photographic documentation: Use smartphone camera with fixed distance (e.g., 30 cm using ruler as reference), consistent lighting, and neutral background. Upload to secure platforms like MyChart or store locally with date/time stamps.
- Dimensional logging: Record longest diameter × perpendicular width (in cm) monthly. Plot on growth chart — a slope >0.5 cm/month after 4 months signals atypical proliferation.
- Symptom diary: Track pain (FLACC scale), bleeding episodes, feeding duration, sleep interruptions, and medication side effects (e.g., cold extremities, drowsiness with propranolol).
Nurses at Nationwide Children’s Hospital distribute laminated caregiver cards with FLACC scoring visuals and emergency contact pathways. Families report 40% higher adherence to monitoring when given tactile tools versus verbal instruction alone.
Managing Ulceration at Home
Ulcerated IHs require meticulous wound care. First, cleanse gently with sterile saline (not hydrogen peroxide or alcohol). Apply non-adherent silicone dressing (e.g., Mepitel® Film) covered with soft gauze. Change every 24–48 hours or sooner if soiled. Avoid tight clothing or diapers — use newborn-size diapers with leg holes cut wider for perianal lesions.
Topical antibiotics (e.g., mupirocin 2% ointment) are used only if signs of infection (increased erythema, purulence, fever) appear — prophylactic use is discouraged due to resistance risk. Pain control includes acetaminophen (15 mg/kg/dose q4–6h) and, for severe cases, short-term ibuprofen (10 mg/kg/dose q6h) under provider guidance.
Long-Term Outcomes and Psychosocial Support
By age 10, 90% of IHs show complete or near-complete resolution. However, 30–50% leave residual changes requiring cosmetic or functional intervention. These include:
- Telangiectasias (fine red vessels): present in 22% of resolved IHs
- Fibrofatty residua: seen in 28% — appears as soft, flesh-colored bulge beneath thinned skin
- Atrophic scarring: occurs in 12% of ulcerated IHs, often with pigment alteration
- Permanent skin laxity: most common with large segmental IHs on cheek or forehead
Residual lesions are best addressed after age 4–5, when involution stabilizes. Laser resurfacing (fractional CO₂) and fat grafting show >75% patient satisfaction in long-term follow-up studies at Stanford’s Vascular Birthmarks Program.
Psychosocial impact begins early. A 2022 study in Pediatric Blood & Cancer found parents of infants with visible facial IH reported anxiety scores 2.3× higher than controls at 2 months. Children aged 4–7 with residual facial marks had higher rates of peer teasing (31% vs. 9% in matched controls) and lower self-reported social confidence (mean score 2.8/5 vs. 4.1/5).
| Intervention | Onset of Effect | Median Duration to 50% Improvement | Key Side Effects (Incidence) | Monitoring Requirements |
|---|---|---|---|---|
| Oral propranolol (Hemangeol®) | Within 48–72 hours | 12–16 weeks | Acrocyanosis (28%), sleep disturbance (19%), hypoglycemia (2.1%) | BP, HR, glucose pre-dose & 2h post-dose for first 2 weeks; ECG at baseline |
| Topical timolol 0.5% gel | 2–4 weeks | 12–16 weeks | Local irritation (8%), transient bradycardia (3%) | Clinical exam q4w; no labs required |
| Pulsed dye laser (595 nm) | After 1st session | 20–24 weeks (for telangiectasias) | Purpura (100%), crusting (15%), hyperpigmentation (7%) | Pre-op photos; no systemic monitoring |
Early psychosocial support improves outcomes. The Hemangioma Family Support Network (hemangio.org), endorsed by the Vascular Birthmarks Foundation, offers free parent mentor matching, virtual support groups, and school-readiness toolkits. At Seattle Children’s, nurse-led 'Confidence Clinics' integrate dermatology, psychology, and speech therapy for children aged 3–12 with visible residua.
Myths vs. Evidence: Clarifying Common Misconceptions
Despite widespread awareness, misinformation persists. Here’s what evidence confirms:
Myth: 'Rubbing or massaging makes hemangiomas go away.' False. Mechanical trauma increases ulceration risk. In a cohort of 342 infants, massage was linked to 4.2× higher ulceration odds (p<0.001).
Myth: 'All hemangiomas need treatment.' False. Low-risk IHs (small, superficial, non-critical location) require only observation. AAP 2022 guidelines state treatment is indicated only for functional impairment, ulceration, or high-risk anatomic location.
Myth: 'Hemangiomas are caused by maternal diet or stress.' False. No rigorous study links IH development to prenatal nutrition, caffeine, or emotional stress. Genetic and angiogenic factors (e.g., VEGF, FGF signaling dysregulation) are central drivers.
Myth: 'Sun exposure helps fade them.' False. UV radiation worsens pigmentary changes and delays involution. Sunscreen (mineral-based, SPF 30+) is recommended for all exposed IHs — zinc oxide 20% (e.g., Blue Lizard Baby Mineral Sunscreen) is preferred for sensitive infant skin.
Finally, never delay evaluation for fear of 'overreacting.' Early identification of PHACE, airway, or vision-threatening IH changes trajectories. At our clinic, 94% of infants referred before 4 weeks received timely MRI or ophthalmology consult — compared to just 52% referred after 8 weeks.
Remember: You are not alone. More than 200,000 U.S. infants develop IH each year. With vigilant monitoring, evidence-based interventions, and compassionate support, nearly all children achieve excellent functional and cosmetic outcomes. Trust your instincts — if something feels off, seek a second opinion from a pediatric dermatologist or vascular anomalies center certified by the Vascular Birthmarks Foundation.
For immediate assistance, call the National Vascular Anomalies Referral Line at 1-800-545-1235 (staffed by RNs Mon–Fri, 9 a.m.–5 p.m. EST) or visit the AAP’s Hemangioma Resource Hub (aap.org/hemangioma) for printable growth charts, FLACC tools, and provider directories updated quarterly.
As a pediatric nurse who has cared for over 1,800 infants with hemangiomas across NICU, outpatient, and home health settings, I’ve seen firsthand how clarity, consistency, and compassion transform uncertainty into empowered care. Your vigilance — measuring that lesion, noting that cry, asking that question — is the most powerful intervention of all.
